Related Experiment Video
Updated: Aug 13, 2026
04:46
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence
Bogdan Mircea Măciuceanu Zărnescu1, Denisa Nicoleta Mușat2, Adelina-Gabriela Niculescu2,3
1University of Medicine and Pharmacy "Carol Davila", 8, Eroii Sanitari, 050474 Bucharest, Romania.
Nanomaterials (Basel, Switzerland)
|August 12, 2026
Summary
Hydrogel-nanoparticle composites offer a novel solution to prevent tumor recurrence after surgery. These advanced materials fill resection gaps, release drugs locally, and remodel the tumor microenvironment to improve patient outcomes.
Area of Science:
- Biomaterial Science
- Nanomedicine
- Oncology
Background:
- Tumor recurrence post-resection is a major cause of cancer mortality.
- Residual disease in the resection cavity resists conventional therapies.
- Hydrogel-nanoparticle (HNP) composites offer localized therapeutic strategies.
Purpose of the Study:
- To review the biological basis and design principles of localized post-surgical therapy.
- To compile evidence for the efficacy of HNP platforms in reducing tumor recurrence.
- To discuss advanced HNP strategies and translational challenges.
Main Methods:
- Review of biological foundations for localized post-surgical therapy.
- Analysis of physicochemical properties of hydrogel and nanoparticle components.
- Compilation of mechanistic and preclinical data on HNP platforms.
Main Results:
- HNPs are designed to fill surgical gaps and provide sustained local drug delivery.
- HNPs can energetically remodel the post-surgical tumor microenvironment.
- Evidence supports HNP platforms in reducing local recurrence and improving outcomes.
Conclusions:
- HNP platforms represent a promising approach to combat post-surgical tumor recurrence.
- Advanced strategies include immunomodulation, stimuli-responsive release, and combination therapies.
- Addressing manufacturing, biocompatibility, and regulatory aspects is crucial for clinical translation.
